Prescription of Psychotropic Medicines to Pregnant Women in Nord-Pas-de-Calais, France.

被引：3

作者：

Danel, Thierry ^{[1
,2
]}

Plancke, Laurent ^{[1
,3
]}

Amariei, Alina ^{[1
]}

Benoit, Emmanuel ^{[4
]}

Gautier, Sophie ^{[2
,6
]}

Capele, Corinne ^{[5
]}

Vaiva, Guillaume ^{[1
,2
,6
]}

机构：

[1] Federat Reg Rech Sante Mentale Nord Pas de Calais, F-59000 Lille, France

[2] CHRU Lille, Lille, France

[3] Ctr Iillois Etud & Rech Sociol & Econ, Lille, France

[4] Caisse Natl Assurance Malad Travailleurs Salaries, Serv Med Reg Nord Picardie, Villeneuve Dascq, France

[5] Etab Publ Sante Mentale Agglomerat Lilloise, St Andre Lez Lille, France

[6] Univ Lille Nord France, Lille, France

来源：

THERAPIE | 2013年 / 68卷 / 01期

关键词：

psychotropic medicine; pregnancy; teratogenticity; fetal damage; SEROTONIN REUPTAKE INHIBITORS; RISK; MEDICATION; DISORDERS;

D O I：

10.2515/therapie/2013005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Prescription of Psychotropic Medicines to Pregnant Women in Nord-Pas-de-Calais, France. Aim. Prescription of psychotropic medicines carries risks to pregnancy. It is therefore appropriate to measure the prescription rate of these compounds in pregnant women. Method. We studied the prescription rate for psychotropic agents to pregnant women from the Cnamts medicines reimbursement data and we compared this to prescriptions in non-pregnant women in the same age group. Results. There is a fall in the use of psychotropic agents in women during pregnancy compared to a non-pregnant population of the same age. Pregnant women receive 2.17 times less psychotropic agents. Nevertheless, approximately one out of every twenty women is prescribed a proprietary product with known risk to the neonate and four out of a thousand are prescribed a proprietary product which carries a risk of malformation during the first trimester. Conclusion. Medical practice takes account of embryo-fetal risk in prescribing psychotropic agents in general although more communication is needed about the risk of some compounds during pregnancy.

引用

页码：31 / 36

页数：6

共 19 条

[1]

Autret-Leca E, 2011, THERAPIE, V5, P431

[2] Update on the pharmacologic management of neonatal abstinence syndrome [J].

Bio, L. L. ;

Siu, A. ;

Poon, C. Y. .

JOURNAL OF PERINATOLOGY, 2011, 31 (11) :692-701

[3]

Direction de la Securite sociale, CHIFFR CLES SEC SOC

[4] The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium [J].

Dodd, Seetal ;

Berk, Michael .

CURRENT DRUG SAFETY, 2006, 1 (01) :25-33

[5] Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy [J].

Einarson, Adrienne ;

Pistelli, Alessandra ;

DeSantis, Marco ;

Malm, Heli ;

Paulus, Wolfgang D. ;

Panchaud, Alice ;

Kennedy, Debra ;

Einarson, Thomas R. ;

Koren, Gideon .

AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (06) :749-752

[6] Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: Risk for the foetus and the newborn [J].

Favreliere, S. ;

Nourrisson, A. ;

Jaafari, N. ;

Pochat, M. -C. Perault .

ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2010, 36 :D133-D138

[7] A review of the use of psychotropic medication in pregnancy [J].

Galbally, Megan ;

Snellen, Martien ;

Lewis, Andrew J. .

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2011, 23 (06) :408-414

[8]

Galbally M, 2010, AUST NZ J PSYCHIAT, V44, P967, DOI 10.3109/00048674.2010.506637

[9]

Gasquet I, 2005, ENCEPHALE, V31, P195

[10] Drug treatment for mood disorders in pregnancy [J].

Gentile, Salvatore .

CURRENT OPINION IN PSYCHIATRY, 2011, 24 (01) :34-40

← 1 2 →